Isochol (Hymecromone)

Hymecromone is converted in the body to 4‑methylumbelliferone, which stimulates hepatic synthesis of bile acids and promotes their secretion into the biliary tract. The increased bile‑acid pool accelerates bile flow, reducing bile stasis and assisting in the management of cholestatic disorders.

The dosage of Isochol is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, severity of disease, and response to therapy. No fixed regimen is provided here; the prescribing clinician will set the appropriate dose.

Safety data for Hymecromone in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit to the mother clearly outweighs any possible risk to the fetus or infant. Consultation with a healthcare professional is essential before use in these populations.

To request Isochol, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The most common alternative for cholestatic liver disorders is ursodeoxycholic acid (UDCA). While UDCA primarily protects cholangiocytes and improves bile composition, Hymecromone (Isochol) directly stimulates bile‑acid synthesis and flow. Choice of therapy depends on the specific clinical scenario, physician preference, and patient tolerance.

Isochol should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Isochol is taken orally, typically with a glass of water. The exact timing relative to meals should follow the prescribing clinician’s instructions, as food may influence absorption in some patients.

Serious adverse events, although rare, include allergic reactions such as hives, swelling, or anaphylaxis, as well as significant liver enzyme elevations indicating hepatotoxicity or cholestatic hepatitis. Patients should seek immediate medical attention if they experience rash, jaundice, severe abdominal pain, or signs of an allergic reaction.

Isochol is contraindicated in individuals with known hypersensitivity to Hymecromone or any of its excipients. Caution is also advised for patients with severe hepatic impairment, active liver disease, or those taking medications that may cause serious hepatotoxic interactions. Pregnant or breastfeeding women should only use it if clearly indicated by a healthcare professional.